Litcius/Paper detail

Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells

Luca Gerosa, Christopher Chidley, Fabian Fröhlich, Gabriela Sánchez, Sang Kyun Lim, Jeremy L. Muhlich, Jia-Yun Chen, Sreeram Vallabhaneni, Gregory J. Baker, Denis Schapiro, Mariya Atanasova, Lily A. Chylek, Tujin Shi, Lian Yi, Carrie Nicora, Allison Claas, Thomas S.C. Ng, Rainer H. Köhler, Douglas A. Lauffenburger, Ralph Weissleder, Miles A. Miller, Weijun Qian, H Wiley, Peter K. Sorger

2020Cell Systems116 citationsDOIOpen Access PDF

Abstract

monomer-driven configuration that is drug sensitive to a receptor-driven configuration that involves Ras-GTP and RAF dimers and is highly resistant to RAF and MEK inhibitors. Altogether, this work shows that pulsatile MAPK activation by factors in the microenvironment generates a persistent population of melanoma cells that rewires MAPK signaling to sustain non-genetic drug resistance.

Topics & Concepts

MAPK/ERK pathwayAutocrine signallingCell biologyBiologyMelanomaCancer researchSignal transductionMEK inhibitorParacrine signallingReceptorGeneticsMelanoma and MAPK PathwaysCellular Mechanics and InteractionsComputational Drug Discovery Methods
Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells | Litcius